Lanvin Group Holdings Limited (LANV)
NYSE: LANV · Real-Time Price · USD
1.690
+0.021 (1.27%)
Oct 31, 2024, 3:59 PM EDT - Market closed
Lanvin Group Revenue
Lanvin Group had revenue of 170.98M EUR in the half year ending June 30, 2024, a decrease of -15.23%. This brings the company's revenue in the last twelve months to 382.62M, down -12.07% year-over-year. In the year 2023, Lanvin Group had annual revenue of 426.18M with 0.92% growth.
Revenue (ttm)
382.62M EUR
Revenue Growth
-12.07%
P/S Ratio
0.48
Revenue / Employee
145,096 EUR
Employees
2,637
Market Cap
198.26M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 426.18M | 3.87M | 0.92% |
Dec 31, 2022 | 422.31M | 113.49M | 36.75% |
Dec 31, 2021 | 308.82M | 86.21M | 38.73% |
Dec 31, 2020 | 222.61M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLANV News
- 2 months ago - PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada - Business Wire
- 2 months ago - Lanvin Group Holdings Limited (LANV) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Lanvin Group Posts Revenue of €171 million in H1 2024 - PRNewsWire
- 3 months ago - SERGIO ROSSI APPOINTS PAUL ANDREW CREATIVE DIRECTOR - PRNewsWire
- 4 months ago - LANVIN APPOINTS PETER COPPING ARTISTIC DIRECTOR - PRNewsWire
- 5 months ago - Regis Rimbert Named CEO of Wolford AG - PRNewsWire
- 5 months ago - ees Europe: Battery Storage – Powerbanks for the Energy Transition - Business Wire
- 5 months ago - BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive Therapies in Lowering Symptomatic Burden of Polycythemia Vera (PV): Real-World Analysis Published at ASCO - Business Wire